Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Blood (2024) 144 (24): 2554–2557.

https://doi.org/10.1182/blood.2024026605

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Shreyas Khanna, Harini Haran, Thomas Wiseman, Kevin Hung, Aidan Sapio, Philip Selby, Michaela Spooner, David T Yeung, Daniel Thomas, Chung How Kok, Andrew H Wei, Chong Chyn Chua, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 4237.

https://doi.org/10.1182/blood-2024-209258

Published: 2024

Journal Articles

Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis

Stephen Ting, Kieran Fleming, Pooranee Morgan, Natasha S. Anstee, Andrew H Wei, Peter Meikle, Andrew Murphy

Blood (2024) 144 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2024-207280

Published: 2024

Journal Articles

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Zhi Han Yeoh, Ing Soo Tiong, Mark R Dowling, Hamish W Scott, Nicole O'Leary, Samantha van der Linde, Tamia Nguyen, Simon J Harrison, Ashish Bajel, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 653.

https://doi.org/10.1182/blood-2024-204494

Published: 2024

Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Blood (2024) 144 (Supplement 1): 223.

https://doi.org/10.1182/blood-2024-202895

Published: 2024

Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Blood (2024) 144 (Supplement 1): 218.

https://doi.org/10.1182/blood-2024-201058

Published: 2024

Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Blood (2024) 144 (Supplement 1): 217.

https://doi.org/10.1182/blood-2024-199882

Published: 2024

Journal Articles

CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Donia M. Moujalled, Giovanna Pomilio, Thomas Morley, Veronique Litalien, Natasha S. Anstee, Sun Loo, Zhi-Han Yeoh, Clovis Boibessot, Laura Bresson, Ana-Leticia Maragno, Caroline Liot, Andrew H Wei

Blood (2024) 144 (Supplement 1): 4136.

https://doi.org/10.1182/blood-2024-202691

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

Rithin Nedumannil, Chelsea Matley, Ashish Bajel, Mark J. Levis, Andrew H Wei

Blood (2024) 144 (Supplement 1): 6060.

https://doi.org/10.1182/blood-2024-194547

Published: 2024

Journal Articles

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Anoop K Enjeti, Suthanthirakannan Ramamoorthy, Devendra Hiwase, Asma Ashraf, Belinda E Butcher, Sushma Kollipara, Carolyn S. Grove, Andrew H Wei, Jake Shortt

Blood (2024) 144 (Supplement 1): 4605.1.

https://doi.org/10.1182/blood-2024-202604

Published: 2024

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

How I Treat patients with AML using azacitidine and venetoclax

Andrew H. Wei, Sun Loo, Naval G Daver

Blood blood.2024024009.

https://doi.org/10.1182/blood.2024024009

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Shaun Fleming, Xavier Cheng-Hong Tsai, Rhiannon Morris, Hsin-An Hou, Andrew H. Wei

Blood (2023) 142 (23): 2029–2033.

https://doi.org/10.1182/blood.2023020855

Published: 2023

Includes: Supplemental data

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 702.

https://doi.org/10.1182/blood-2023-180720

Published: 2023

Journal Articles

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Chun Yew Fong, Natasha Anstee, Ing Soo Tiong, Chong Chyn Chua, Jad Othman, Hannah Renshaw, Robert Baker, Nigel H. Russell, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2023-185541

Published: 2023

NARROW

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

How I Treat patients with AML using azacitidine and venetoclax

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only